The company has substantially improved this development of a novel solution for cardiac amyloidosis, utilizing the compound. Initial trial data reveals promising outcomes for individuals affected from this severe illness. The focus highlights the company’s dedication to treating unmet medical demands in a heart disease field. Attruby: BridgeBio'